New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005
Management of adverse drug events in TB therapy Source: Eur Respir Mon 2012; 58: 167-193 Year: 2012
Tuberculosis therapy: past, present and future Source: Eur Respir J 2002; 20: 87S-94S Year: 2002
Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter? Source: Eur Respir J 2007; 29: 347-351 Year: 2007
Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007
Efficacy and safety of modified anti-tubercular treatment(ATT) regimens in treatment of tuberculosis(TB) in patients with underlying chronic liver disease(CLD) Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 650s Year: 2005
The experience of overcome of Mcb.tuberculosis resistance to antituberculosis drugs Source: Eur Respir J 2002; 20: Suppl. 38, 613s Year: 2002
Prevalence of inappropriate tuberculosis treatment regimens: a systematic review Source: Eur Respir J 2012; 39: 1012-1020 Year: 2012
Therapeutic options for sarcoidosis: old and new Source: Annual Congress 2005 - PG15 - Therapeutic options for interstitial lung diseases in 2005 Year: 2005
Chemotherapy efficacy in TB patients resistant to major and reserve drugs Source: Eur Respir J 2005; 26: Suppl. 49, 648s Year: 2005
Two major problems in TB patients today: MDR and the abandoned therapy Source: Annual Congress 2011 - Challenges in tuberculosis control Year: 2011
Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009
The effectiveness of TB treatment in patients with gastrointestinal tract disorders, depending on the way of administration of anti-TB drugs Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012
Macrolide therapy in asthma: limited treatment, long-term improvement Source: Eur Respir J 2009; 33: 1239 Year: 2009
Severe adverse effects of antitubercular drugs and patient management Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Multi-drug resistant tuberculosis (MDR-TB) in Ramnicul Valcear, Romania; drug treatment, resistance testing and adverse drug reactions Source: Eur Respir J 2006; 28: Suppl. 50, 378s Year: 2006
Can toxicities induced by antituberculosis drugs be better managed in diabetic patients? Source: Eur Respir J, 50 (1) 1700409; 10.1183/13993003.00409-2017 Year: 2017
Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016